• Mycobacterium tuberculosis and the response of its host
• 34 min
  1. The genetic structure of Mycobacterium tuberculosis - insights into genome organisation and evolution of the causative agent of tuberculosis

  • Dr. Roland Brosch
• 36 min
  2. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 57 min
  3. Immune response and rational development of vaccines and biomarkers

  • Prof. Dr. Stefan H. E. Kaufmann
• 38 min
  4. Molecular mechanisms of drug resistance in M. tuberculosis

  • Dr. Daniela Cirillo
• The epidemiology of tuberculosis
• 40 min
  5. The basic epidemiology of tuberculosis (TB)

  • Dr. David Dowdy
• 34 min
  6. Global epidemiology of TB

  • Dr. Philippe Glaziou
• 48 min
  7. Social determinants of tuberculosis

  • Dr. Knut Lönnroth
• The control of tuberculosis
• 46 min
  8. Treatment of tuberculosis

  • Dr. Jean-Pierre Zellweger
• 32 min
  9. The End TB Strategy towards TB elimination 1

  • Dr. Mario Raviglione
• 52 min
  10. The End TB Strategy towards TB elimination 2

  • Dr. Mario Raviglione
• 38 min
  11. Financing TB care and control

  • Dr. Christopher Fitzpatrick
  • Dr. Andrea Pantoja
• 27 min
  12. Tuberculosis and COVID-19

  • Prof. Giovanni Battista Migliori
• 36 min
  13. Multidrug resistant tuberculosis (MDR-TB): an update

  • Dr. Simon Tiberi
• 49 min
  14. Impact of HIV on tuberculosis in the developing world and how to manage it

  • Prof. Anthony D. Harries
• 33 min
  15. Reaching the missing millions through public-private mix (PPM) for TB prevention and care

  • Ms. Hannah Monica Dias
• 39 min
  16. TB in children

  • Prof. Ben J. Marais
• 30 min
  17. Community engagement in tuberculosis care

  • Ms. Lana Syed
• 29 min
  18. India: the epicentre of global TB control

  • Dr. Madhukar Pai
• 23 min
  19. Community engagement in TB care

  • Dr. Haileyesus Getahun
• Research and development for new approaches in the control of tuberculosis
• 21 min
  20. Development of new regimens for tuberculosis

  • Dr. Zhenkun Ma
• 35 min
  21. Development, testing and introduction of new diagnostic tools for tuberculosis

  • Dr. Mark Perkins
• 69 min
  22. Pharmacometrics in tuberculosis

  • Prof. Charles A. Peloquin
• 29 min
  23. Extrapulmonary tuberculosis

  • Dr. Scott Heysell
• 27 min
  24. The role of surgery in tuberculosis management

  • Dr. Richard Zaleskis
• Archived Lectures *These may not cover the latest advances in the field
• 28 min
  25. The development of current treatments for tuberculosis

  • Dr. Andrew Nunn
• 47 min
  26. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 34 min
  27. Basics of tuberculosis epidemiology

  • Prof. Frank Cobelens
• 40 min
  28. Drug resistance in tuberculosis and its public health management

  • Dr. Paul Nunn
• 57 min
  29. The international approach to the control of tuberculosis

  • Dr. Mario Raviglione
• 35 min
  30. Public-private mix for TB care and control

  • Dr. Mukund Uplekar

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Drug resistant (DR) tuberculosis: current scenario
3. Multi drug resistant tuberculosis
4. Extensively drug resistant tuberculosis
5. Importance of understanding DR mechanisms
6. Diagnosis of drug resistance
7. Technical challenges of conventional DST
8. WHO policies
9. LPA performance in isolates and clinical samples
10. Main anti-TB drugs and mechanisms of action
11. Mechanisms of drug resistance acquisition
12. Development of drug resistant tuberculosis
13. Drug resistant TB is a man-made disease
14. Clinical relevance of drugs resistance
15. Mechanisms of drug resistance in tuberculosis
16. Isoniazid: targeting mycolic acid biosynthesis
17. Ethionamide
18. ethA mutations and ethionamide resistance
19. Other genes correlated to ethionamide resistance
20. Rifampicin
21. Low concordance of "rare mutations": MGIT DST
22. Pyrazinamide - Mechanism of action
23. Pyrazinamide - Mechanisms of resistance
24. Ethambutol
25. Role of point mutations in outcome prediction
26. Fluoroquinolones
27. Second line injectable drugs
28. Fluoroquinolones & injectables: commercial tests
29. PAS
30. Linezolid
31. Point mutations and drug resistance
32. Conclusions
33. Acknowledgements

Topics Covered

• Drug resistant tuberculosis epidemic
• Mechanisms of drug resistance in M.tuberculosis
• Mechanisms of drug resistance to first and second line antitubercular drugs
• Considerations on currently available molecular tests for the diagnosis of drug resistant tuberculosis

Links

Series:

• Tuberculosis

Categories:

• Microbiology

Therapeutic Areas:

• Infectious Diseases
• Respiratory Diseases

Talk Citation

Publication History

• Published on February 28, 2013

Financial Disclosures

• Dr. Daniela Cirillo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.